<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41528">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02565758</url>
  </required_header>
  <id_info>
    <org_study_id>M15-394</org_study_id>
    <secondary_id>2015-001645-84</secondary_id>
    <nct_id>NCT02565758</nct_id>
  </id_info>
  <brief_title>ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors</brief_title>
  <official_title>A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label dose escalation study designed to evaluate the safety and
      pharmacokinetics of ABBV-085 and determine the recommended Phase 2 dose (as monotherapy or
      in combination with standard therapies) in subjects with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Collect all adverse events at each visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of ABBV-085.</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half life of ABBV-085.</measure>
    <time_frame>UP to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from time zero to the last measurable concentration AUC(0-t) of ABBV-085.</measure>
    <time_frame>Up 24 months</time_frame>
    <description>AUC (0-t) = Area under the serum concentration curve from time zero (pre-dose) to the time of the last measurable concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>ORR is defined as the proportion of the participants who achieve a complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>PFS is defined as the time from the first dose date of ABBV-085 to either disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response (DOR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>DOR is defined as the time from the participant's initial CR or PR to the time of disease progression.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Advanced Solid Tumor Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (ABBV-085)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-085 will be administered at escalating dose levels in 28-day cycles. Additional participants will be enrolled in a cohort that will further evaluate ABBV-085.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (ABBV-085 plus Nivolumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-085 to be evaluated with Nivolumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (ABBV-085 plus Gemcitabine +/- nab-paclitaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abbv-085 to be evaluated with Gemcitabine +/- nab-paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-085</intervention_name>
    <description>Administered as an intravenous infusion in 28-day dosing cycles.</description>
    <arm_group_label>Arm A (ABBV-085)</arm_group_label>
    <arm_group_label>Arm B (ABBV-085 plus Nivolumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>It is an intravenous infusion administered every 14 days.</description>
    <arm_group_label>Arm B (ABBV-085 plus Nivolumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>It is an intravenous infusion administered on day 1, 8 and 15 of a 28-day cycle.</description>
    <arm_group_label>Arm C (ABBV-085 plus Gemcitabine +/- nab-paclitaxel)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>It is an intravenous infusion administered on day 1, 8 and 15 of a 28-day cycle.</description>
    <arm_group_label>Arm C (ABBV-085 plus Gemcitabine +/- nab-paclitaxel)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants with advanced solid tumor that is not amenable to surgical resection or
             other approved therapeutic options.

          2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.

          3. Participants must have measurable disease per Response Evaluation Criteria In Solid
             Tumors (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens:

             - Participants with non-evaluable or non-measurable cancer are eligible if they have
             a confirmed increase in tumor antigens &gt;=2 x upper limit of normal (ULN).

          4. All participants must consent to provide archived diagnostic formalin-fixed paraffin
             embedded (FFPE) tumor tissue, if available.

          5. Participant has adequate bone marrow, renal, hepatic and cardiac function.

          6. Women of childbearing potential must have a negative serum pregnancy test within 14
             days prior to initiation of treatment.

        Exclusion Criteria:

          1. Participant has received anticancer therapy or any investigational therapy within a
             period of 21 days prior to the first dose of ABBV-085.

          2. Uncontrolled metastases to the central nervous system (CNS). Participants with brain
             metastases are eligible provided they have shown clinical and radiographic stable
             disease for at least 4 weeks after definitive therapy and have not used steroids for
             at least 4 weeks prior to first dose of ABBV-085.

          3. Unresolved adverse events &gt;= Grade 2 from prior anticancer therapy, except for
             alopecia.

          4. Participant has ongoing hemolysis.

          5. Major surgery within &lt;=28 days prior to the first dose of ABBV-085.

          6. Clinically significant uncontrolled condition(s).

          7. Participant has history of major immunologic reaction to any auristatin-based and /or
             Immunoglobulin G (IgG) containing agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominic Lai, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847-283-8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148586</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148586, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148581</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148581, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148579</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148579, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 143782</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 143782, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 149777</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 149777, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151348</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151348, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150786</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150786, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148200</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148200, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148583</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148583, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148652</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148652, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148580</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148580, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147681</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147681, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 141715</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 141715, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148584</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148584, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150300</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150300, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150799</name>
      <address>
        <city>Madrid (Espana)</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150799, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148564</name>
      <address>
        <city>Madrid, Espana</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148564, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 146039</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 27, 2017</lastchanged_date>
  <firstreceived_date>September 30, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Cancer</keyword>
  <keyword>Neoplasm</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
